
Repligen Corporation
NASDAQ:RGEN
145.37 (USD) • At close March 12, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Repligen Corporation |
Symbool | RGEN |
Munteenheid | USD |
Prijs | 145.37 |
Beurswaarde | 8,144,601,379 |
Dividendpercentage | 0% |
52-weken bereik | 113.5 - 200.23 |
Industrie | Medical Instruments & Supplies |
Sector | Healthcare |
CEO | Mr. Anthony J. Hunt |
Website | https://www.repligen.com |
An error occurred while fetching data.
Over Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)